

September 1, 2023

Pharmacy Information and Preferred Drug List Changes – Additional 3Q2023 Coverage Updates

This update applies to Trillium Community Health Plan's Oregon Health Plan

CHANGE TO ADALIMUMAB PREFERRED PRODUCTS

As health care expenditures rise, biosimilar drugs represent a clear opportunity to reduce healthcare costs while maintaining patient access to vital therapies. Described by the US Food and Drug Administration (FDA), a biosimilar is a “biological product that is highly similar to the reference product notwithstanding mirror differences in clinical inactive components.” “There are no clinically meaningful differences between the biological product and the reference product in terms of the safety, purity, and potency of the product.”^{1,2} We constantly innovate and deliver personal, caring service for our members.

Effective 10.1.2023 Trillium is making a change to their preferred adalimumab products. The reference product, Humira, will no longer preferred for members initiating treatment; current members being treated with Humira will be able to continue treatment with the reference product. See the table below for list of preferred adalimumab biosimilars and formulations.

Reference Product	Preferred Biosimilar	Preferred Formulations
HUMIRA® (ADALIMUMAB)	Adalimumab-adaz (Hyrimoz) • Sandoz Inc.	<ul style="list-style-type: none"> • Single-dose prefilled glass syringe (with BD UltraSafe Passive™ Needle Guard): 40 mg/0.4 mL • Single-dose prefilled pen (Sensoready® Pen): 40 mg/0.4 mL
	Adalimumab-aqvh (Yusimry) • Coherus BioSciences	<ul style="list-style-type: none"> • Single-dose prefilled pen (Yusimry Pen): 40 mg/0.8 mL • Single-dose prefilled glass syringe: 40 mg/0.8 mL
	Adalimumab-bwwd (Hadlima) • Samsung Bioepis Co., Ltd.	<ul style="list-style-type: none"> • Single-dose prefilled autoinjector (Hadlima PushTouch): 40 mg/0.8 mL, 40 mg/0.4 mL (citrate-free) • Single-dose prefilled syringe: 40 mg/0.8 mL, 40 mg/0.4 mL (citrate-free)
	Adalimumab-fkjp (Hulio) • Mylan Pharmaceuticals Inc.	<ul style="list-style-type: none"> • Single-dose prefilled pen (Hulio Pen): 40 mg/0.8 mL • Single-dose prefilled syringe: 40 mg/0.8 mL, 20 mg/0.4 mL

1 Daller J. Biosimilars: A consideration of the regulations in the United States and European Union. Regulatory Toxicology and Pharmacology. 2016 Apr;76:199-208. Doi: 10.1016/j.yrtph.2015.12.013.

2 US Food and Drug Administration. Review and Approval. URL: <https://www.fda.gov/drugs/biosimilars/review-and-approval>.

TRILLIUM COMMUNITY HEALTH PLAN PREFERRED DRUG LIST CHANGES

Trillium's Preferred Drug List (PDL) is updated monthly and is available online.

- See the table below for a summary of recent PDL changes. For the most current preferred drug list, visit the [Pharmacy section of our website](#).

Medication	Effective Date
Additions	
Adalimumab-adaz 40mg/0.4mL Auto-Injector and Prefilled Syringe Added to PDL; PA required	10.1.2023
Adalimumab-fkjp 20mg/0.4mL Prefilled Syringe & 40mg/0.8mL Auto-Injector & Prefilled Syringe Added to PDL; PA required	10.1.2023
BioThrax Anthrax Vaccine Adsorbed Added to PDL	10.1.2023
Dengvaxia Dengue Virus Vaccine Live Tetravalent Added to PDL	10.1.2023
Hadlima (adalimumab-bwwd) 40mg/0.4mL & 40mg/0.8mL PushTouch Auto-Injector & Prefilled Syringe Added to PDL; PA required	10.1.2023
Ixiaro Japanese Encephalitis Vaccine Inactivated Adsorbed Added to PDL	10.1.2023
Stamaril Yellow Fever Vaccine Added to PDL	10.1.2023
Typhim Vi Typhoid VI Polysaccharide Vaccine Added to PDL	10.1.2023
Vaxchora Cholera Vaccine Live Attenuated Added to PDL	10.1.2023
Vivotif Typhoid Vaccine Added to PDL	10.1.2023
YF-VAX Yellow Fever Vaccine Added to PDL	10.1.2023
Yusimry (adalimumab-aqvh) 40mg/0.8mL Added to PDL; PA required	10.1.2023
Removals	
Amjevita (adalimumab-atto) 10mg/0.2mL & 20mg/0.4mL Prefilled Syringe & 40mg/0.8mg Auto-Injector Removed from PDL. Current utilizers will be grandfathered.	10.1.2023
Cimzia (certolizumab pegol) 200mg/ml Prefilled Syringe Removed from PDL. Current utilizers will be grandfathered.	10.1.2023
Enbrel (etanercept) 25mg/0.5mL Prefilled Syringe & 50mg/mL Auto-Injector & Prefilled Syringe Removed from PDL. Current utilizers will be grandfathered.	10.1.2023
Humira (adalimumab) 10mg/0.1ml, 20mg/0.2ml Prefilled Syringe & 40mg/0.8ml, 40mg/0.4ml, 80mg/0.8ml Pen-Injector & Prefilled Syringe Removed from PDL. Current utilizers will be grandfathered.	10.1.2023
Simponi (golimumab) 50mg/0.5mL, 100mg/ml Auto-Injector & Prefilled Syringe & 50 mg/4mL IV Solution Removed from PDL. Current utilizers will be grandfathered.	10.1.2023

Changes	
Buprenorphine HCl-Naloxone 8-2mg HCl SL Film Increased QL to 4 per day	10.1.2023
Rosuvastatin 5mg, 10mg, 20mg & 40 mg Tab Removed ST requirement to try atorvastatin or simvastatin first	10.1.2023
Sublocade (buprenorphine) ER 100mg/0.5mL & 300mg/1.5mL Prefilled Syringe Removed PA requirement for coverage through Medical and Pharmacy benefits	10.1.2023
Zolpidem 5mg Tab Added QL of 2 per day to restrict use to max FDA approved dose. Current utilizers over QL will be grandfathered	10.1.2023
Zolpidem 10mg Tab Added QL of 1 per day to restrict use to max FDA approved dose. Current utilizers over QL will be grandfathered	10.1.2023
Key: PA = prior authorization; PDL = preferred drug list; QL = quantity limit	

PRIOR AUTHORIZATION CHANGES TO SPECIALIZED MEDICATIONS GIVEN IN OFFICE

See the table below for list of new HCPC codes. These codes now require prior authorization for coverage for Trillium Oregon Health Plan members.

Brand (Generic Name)	HCPC Code	Description
Leqembi (lecanemab-irmb)	J0174	INJECTION, LECANEMAB-IRMB, 1 MG

ADDITIONAL INFORMATION

For additional information regarding changes to the Trillium Preferred Drug List (PDL), contact Trillium by telephone at 1-877-600-5472. For the most current version of the PDL, visit the [Trillium website](#).

For additional information on medication coverage guidelines visit the [Provider Resources section](#) of Trillium's website.

If you have questions regarding the information contained in this update, contact Trillium Provider Services through the [Trillium website](#) or by telephone at 1-877-600-5472.